Although surgery, radiotherapy, and chemotherapy remain the standard weapon in the cancer therapist's arsenal, a number of common human cancers cannot be successfully treated by these methods. With the enormous advances in our understanding of the immune system that have taken place over the past two decades, there has been a growing expectation that immunological approaches to the treatment of cancer will provide new and effective ways to control the disease. Of the several forms of immunotherapy that are being pursued, monoclonal antibodies, cancer vaccines and lymphokines/monokines offer exciting opportunities to harness the extraordinary specificity and efficacy of the immune system in the development of effective cancer therapies. The approach we are taking has been greatly influenced by our laboratory and clinical studies with two IgG3 monoclonal antibodies detecting the gangliosides GD2 and GD3. These antibodies have been shown a) to mediate human complement cytotoxicity and ADCC, b) to induce inflamma- tory reactions in tumor sites, and c) to cause tumor regression in a proportion of patients. In the present proposal, we will extend these findings in melanoma and neuroblastoma, and explore the therapeutic value of inflammatogenic antibodies (IgG2a, IgG3, IgM and IgE) in colon and renal cancer. We will also investigate the ability of cytokines such as TNF, IFN-Y, IL-2 and G-CSF to amplify the selective inflammation induced by monoclonal antibodies at the tumor site, with consequent vascular injury and tumor cell damage. A complementary approach to the use of exogenous cytotoxic antibodies is to induce endogenous antibody production by active immunization with immunogenic cancer antigens. Our past studies have shown that vaccination of melanoma patients with purified GM2 elicits production of IgM antibodies that mediate human complement cytotoxicity for human tumor cells expressing GM2. We plan to continue this approach to active immunization, based on our ongoing search for new immunogenic targets, with the aim of constructing maximally immunogenic vaccines containing glycolipid and glycoprotein antigens that elicit high and sustained levels of circulating cytotoxic antibody. Once this has been achieved, we will test whether antibody induction is associated with delayed tumor recurrence. The unifying theme of this program project is to exploit the biological effector functions of mouse and human antibodies and to augment antibody induced tumor cell injury with lymphokines and monokines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
7P01CA033049-10
Application #
3093499
Study Section
Special Emphasis Panel (SRC (T1))
Project Start
1982-07-01
Project End
1994-02-28
Budget Start
1992-03-05
Budget End
1993-02-28
Support Year
10
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Casey, E; Bournazos, S; Mo, G et al. (2018) A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32:547-549
Budhu, Sadna; Schaer, David A; Li, Yongbiao et al. (2017) Blockade of surface-bound TGF-? on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal 10:
Alidori, Simone; Thorek, Daniel L J; Beattie, Bradley J et al. (2017) Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS One 12:e0183902
Scheinberg, David A; Grimm, Jan; Heller, Daniel A et al. (2017) Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol 46:66-73
Weber, Daniela; Jenq, Robert R; Peled, Jonathan U et al. (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:845-852
Mathias, M D; Sockolosky, J T; Chang, A Y et al. (2017) CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia 31:2254-2257
Chang, Aaron Y; Gejman, Ron S; Brea, Elliott J et al. (2016) Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther 16:979-87
Alidori, Simone; Akhavein, Nima; Thorek, Daniel L J et al. (2016) Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 8:331ra39
Alidori, Simone; Bowman, Robert L; Yarilin, Dmitry et al. (2016) Deconvoluting hepatic processing of carbon nanotubes. Nat Commun 7:12343

Showing the most recent 10 out of 289 publications